Zacks Investment Research Upgrades Supernus Pharmaceuticals, Inc. (SUPN) to “Strong-Buy”

Zacks Investment Research upgraded shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) from a hold rating to a strong-buy rating in a research report report published on Wednesday. Zacks Investment Research currently has $47.00 price target on the specialty pharmaceutical company’s stock.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

Several other brokerages have also weighed in on SUPN. Cantor Fitzgerald reaffirmed a buy rating and set a $49.00 target price on shares of Supernus Pharmaceuticals in a research note on Tuesday, September 19th. Stifel Nicolaus cut shares of Supernus Pharmaceuticals from a buy rating to a hold rating and set a $47.00 price target on the stock. in a research report on Tuesday, September 19th. They noted that the move was a valuation call. Piper Jaffray Companies reissued a hold rating and set a $45.00 price target on shares of Supernus Pharmaceuticals in a research report on Friday, September 8th. BidaskClub raised shares of Supernus Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, August 17th. Finally, Janney Montgomery Scott assumed coverage on shares of Supernus Pharmaceuticals in a research report on Friday, July 14th. They set a neutral rating and a $47.00 price target on the stock. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $49.60.

Shares of Supernus Pharmaceuticals (NASDAQ SUPN) traded up $0.70 during mid-day trading on Wednesday, reaching $37.25. 458,600 shares of the company’s stock traded hands, compared to its average volume of 518,001. The company has a current ratio of 1.82, a quick ratio of 1.74 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $1,909.51, a price-to-earnings ratio of 35.14, a PEG ratio of 1.58 and a beta of 1.30. Supernus Pharmaceuticals has a one year low of $20.33 and a one year high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.02. The company had revenue of $80.40 million during the quarter, compared to analyst estimates of $78.74 million. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The business’s revenue for the quarter was up 41.5% on a year-over-year basis. sell-side analysts anticipate that Supernus Pharmaceuticals will post 1.08 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.themarketsdaily.com/2017/11/12/zacks-investment-research-upgrades-supernus-pharmaceuticals-inc-supn-to-strong-buy.html.

In related news, VP Padmanabh P. Bhatt sold 3,709 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $45.23, for a total value of $167,758.07. Following the sale, the vice president now owns 17,500 shares of the company’s stock, valued at $791,525. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Gregory S. Patrick sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $47.60, for a total transaction of $2,380,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 153,709 shares of company stock worth $7,223,108. 6.70% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of SUPN. Meeder Asset Management Inc. raised its holdings in Supernus Pharmaceuticals by 3,455.2% in the second quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock valued at $103,000 after acquiring an additional 2,315 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Supernus Pharmaceuticals by 278.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock valued at $130,000 after acquiring an additional 2,220 shares in the last quarter. Riverhead Capital Management LLC raised its holdings in Supernus Pharmaceuticals by 91.4% in the second quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock valued at $132,000 after acquiring an additional 1,462 shares in the last quarter. Advisor Group Inc. raised its holdings in Supernus Pharmaceuticals by 13.7% in the second quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock valued at $145,000 after acquiring an additional 410 shares in the last quarter. Finally, Victory Capital Management Inc. raised its holdings in Supernus Pharmaceuticals by 17.7% in the second quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock valued at $148,000 after acquiring an additional 517 shares in the last quarter. 96.11% of the stock is currently owned by hedge funds and other institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply